Replies to post #47996 on Biotech Values

[Nerf]

RPRX -I don't see that as an unreasonable amount of money for a company in revenue and earnings, priced among its peers.


Merck annual sales 22B market cap 113B a factor of 6.5 approximately
Phizer, even with all its problems is still standing at sales of 48 Billion and market cap of 198B a factor of 4.0

schering plough 10.5B sales, 48.3B a factor of 4.6.

These are NOT growth companies, either so the p/s is going to be lower....

IMO the figure of a Billion dollar price tag is well within reason for asking, given that the market cap for an endometriosis drug (NO CURRENT THERAPY BESIDES HYSTERECTOMY) and uterine fibroids (NOT ANY GOOD THERAPY BESIDES HYSTERECOTMY) and they should get it easily, in a strong market environment!

Hope you're loading up it, it isn't going to take long at all to reach the multiples from here.

Disclosure: Long a bunch, for a long time.